Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2A | P28223 | 2/20 | 0.32 |
| ▸ | HTR2C | P28335 | 2/20 | 0.32 |
| ▸ | HTR2B | P41595 | 2/20 | 0.32 |
| ▸ | CCR5 | P51681 | 1/20 | 0.32 |
| ▸ | MAP3K14 | Q99558 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1748796 | 1.00 | HTR2A (0.32) | HTR2AHTR2CHTR2BCCR5MAP3K14 | |
| Hydrochloric Acid SCHEMBL7008388 | 0.97 | HTR2A (0.34) | HTR2AHTR2CHTR2BCCR5 | |
| SCHEMBL29080159 | 0.82 | PNMT (0.31) | — | |
| SCHEMBL30600144 | 0.81 | ALDH1A1 (0.37) | HTR2AHTR2CHTR2BCCR5 | |
| SCHEMBL24535981 | 0.81 | ALDH1A1 (0.37) | HTR2AHTR2CHTR2BCCR5 | |
| Trifluoroacetic Acid SCHEMBL7006009 | 0.80 | SLC6A2 (0.34) | — | |
| SCHEMBL3628793 | 0.73 | MAP3K14 (0.33) | MAP3K14 | |
| SCHEMBL18545242 | 0.73 | MAP3K14 (0.33) | MAP3K14 | |
| SCHEMBL455753 | 0.73 | — | — | |
| SCHEMBL30249644 | 0.73 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 64 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070093480-A1 | Novel pyrrolo (2,3-b)pyridine derivatives, the preparation and the pharmaceutical use thereof in the form of kinase inhibitors | AVENTIS PHARMA S.A. (FR) | 2007-04-26 | — | — | US | claimed |
| EP-1042315-B1 | CYCLIC IMIDE-SUBSTITUTED PYRIDYLALKANE, ALKENE, AND ALKINE CARBOXAMIDES USEFUL AS CYTOSTATIC AND IMMUNOSUPPRESSIVE AGENTS | KLINGE CO CHEM PHARM FAB (DE) | 2004-04-14 | — | — | EP | claimed |
| EP-0728758-B1 | Dioxopyrrolo-pyrrole derivatives | HOFFMANN LA ROCHE (CH) | 2003-10-15 | — | — | EP | claimed |
| EP-1042315-A1 | CYCLIC IMIDE-SUBSTITUTED PYRIDYLALKANE, ALKENE, AND ALKINE CARBOXAMIDES USEFUL AS CYTOSTATIC AND IMMUNOSUPPRESSIVE AGENTS | Klinge Pharma GmbH (DE) | 2000-10-11 | — | — | EP | claimed |
| WO-1999031087-A1 | CYCLIC IMIDE-SUBSTITUTED PYRIDYLALKANE, ALKENE AND ALKINE CARBOXAMIDES USEFUL AS CYTOSTATIC AND IMMUNOSUPPRESSIVE AGENTS | KLINGE PHARMA GMBH (DE) | 1999-06-24 | — | — | WO | claimed |
| US-5686459-A | ANTICOAGULANTS | HOFFMANN-LA ROCHE INC. (US) | 1997-11-11 | — | — | US | claimed |
| US-20260035389-A1 | TETRAHYDROPYRIDOPYRIMIDINE PAN-KRAS INHIBITORS | MIRATI THERAPEUTICS INC (US) | 2026-02-05 | — | — | US | disclosed |
| US-20260015350-A1 | AZAQUINAZOLINE PAN-KRAS INHIBITORS | MIRATI THERAPEUTICS INC (US) | 2026-01-15 | — | — | US | disclosed |
| US-20250368649-A1 | TETRAHYDROPYRIDOPYRIMIDINE PAN-KRAS INHIBITORS | MIRATI THERAPEUTICS INC (US) | 2025-12-04 | — | — | US | disclosed |
| WO-2025236100-A1 | SUBSTITUTED HETEROCYCLIC COMPOUNDS, COMPOSITIONS COMPRISING THEM AND USES THEREOF | Université de Montréal (CA) | 2025-11-20 | — | — | WO | disclosed |
| US-12421253-B2 | Tetrahydropyridopyrimidine pan-KRas inhibitors | Mirati Therapeutics, Inc. (US) | 2025-09-23 | — | — | US | disclosed |
| US-12398154-B2 | Azaquinazoline pan-KRas inhibitors | Mirati Therapeutics, Inc. (US) | 2025-08-26 | — | — | US | disclosed |
| EP-4540254-A1 | TETRAHYDROPYRIDOPYRIMIDINE PAN-KRAS INHIBITORS | Mirati Therapeutics, Inc. (US) | 2025-04-23 | — | — | EP | disclosed |
| US-20020143035-A1 | Hydantoin compounds useful as anti-inflammatory agents | BRISTOL-MYERS SQUIBB COMPANY | 2002-10-03 | — | — | US | disclosed |
| WO-2002044181-A1 | HYDANTOIN COMPOUNDS USEFUL AS ANTI-INFLAMMATORY AGENTS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2002-06-06 | — | — | WO | disclosed |
| EP-1122257-A1 | Benzimidazole compounds as ORL1-receptor agonists | PFIZER INC. (US) | 2001-08-08 | — | — | EP | disclosed |
| EP-1042315-A1 | CYCLIC IMIDE-SUBSTITUTED PYRIDYLALKANE, ALKENE, AND ALKINE CARBOXAMIDES USEFUL AS CYTOSTATIC AND IMMUNOSUPPRESSIVE AGENTS | Klinge Pharma GmbH (DE) | 2000-10-11 | — | — | EP | disclosed |
| WO-1999031087-A1 | CYCLIC IMIDE-SUBSTITUTED PYRIDYLALKANE, ALKENE AND ALKINE CARBOXAMIDES USEFUL AS CYTOSTATIC AND IMMUNOSUPPRESSIVE AGENTS | KLINGE PHARMA GMBH (DE) | 1999-06-24 | — | — | WO | disclosed |
| US-5686459-A | ANTICOAGULANTS | HOFFMANN-LA ROCHE INC. (US) | 1997-11-11 | — | — | US | disclosed |
| EP-0728758-A1 | Dioxopyrrolo-pyrrole derivatives | F. HOFFMANN-LA ROCHE AG (CH) | 1996-08-28 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12421253-B2 | Tetrahydropyridopyrimidine pan-KRas inhibitors | KRAS, NRAS, HRAS | HTR2A 4695/4885HTR2C 4531/4885HTR2B 4533/4885 |
| US-20020143035-A1 | Hydantoin compounds useful as anti-inflammatory agents | HRH4, IL4I1, HRH2 | HTR2A 1846/4885HTR2C 956/4885HTR2B 1254/4885 |
| US-20250368649-A1 | TETRAHYDROPYRIDOPYRIMIDINE PAN-KRAS INHIBITORS | KRAS, NRAS, HRAS | HTR2A 4695/4885HTR2C 4531/4885HTR2B 4533/4885 |
| US-20260015350-A1 | AZAQUINAZOLINE PAN-KRAS INHIBITORS | KRAS, NRAS, HRAS | HTR2A 4594/4885HTR2C 3093/4885HTR2B 4659/4885 |
| US-12398154-B2 | Azaquinazoline pan-KRas inhibitors | KRAS, NRAS, HRAS | HTR2A 4753/4885HTR2C 4397/4885HTR2B 4690/4885 |
| US-20260035389-A1 | TETRAHYDROPYRIDOPYRIMIDINE PAN-KRAS INHIBITORS | KRAS, NRAS, HRAS | HTR2A 4756/4885HTR2C 3286/4885HTR2B 4694/4885 |
| US-20070093480-A1 | Novel pyrrolo (2,3-b)pyridine derivatives, the preparation and the pharmaceutical use thereof in the form of kinase inhibitors | MAP3K19, MAP4K2, MAP3K1 | HTR2A 2906/4885HTR2C 2144/4885HTR2B 1972/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.